Barbara E.
- Country
- Austria
- Department
- Abteilung für Dermatologie und Venerologie
Research Overview
- INCB 18424-320: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Prurigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN2)
- Efficacy of PURETHAL Mites Mixture Subcutaneous Immunotherapy in Adults with Moderate to Severe House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis
- Efficacy and Safety Evaluation of PQ Birch in Patients with Birch Pollen-Induced Seasonal Allergic Rhinitis and Rhinoconjunctivitis
Data & Insights
Has run more than one trial at 62 of 251 partner sites.
Specializations
Allergic Conditions
Specialized in treating allergic rhinitis and rhinoconjunctivitis, with particular focus on environmental triggers such as house dust mites and birch pollen.
- House dust mite allergies
- Seasonal allergic responses
- Immunotherapy approaches
Expertise in both subcutaneous and specialized immunotherapy treatments for respiratory allergies.
Dermatological Disorders
Focuses on complex inflammatory skin conditions, particularly hidradenitis suppurativa and prurigo nodularis.
- Moderate to severe hidradenitis suppurativa
- Advanced prurigo nodularis
- Inflammatory skin diseases
Investigates innovative therapeutic approaches for challenging dermatological conditions.
Treatment Innovations
Explores novel therapeutic agents including povorcitinib, ruxolitinib, and upadacitinib for various medical conditions.
- Advanced immunomodulatory therapies
- Targeted treatment approaches
- Alternative therapeutic options
Specializes in evaluating treatments for patients who have not responded to conventional therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.